Cardinal Sees No Rx Distribution Disruptions After April 1 Fee-For-Service Deadline
This article was originally published in The Pink Sheet Daily
Executive Summary
Most drug manufacturers have agreed in principle to fee-for-service distribution contracts, Cardinal CEO Walter says. Negotiations are now focused on price, not the methodology for paying wholesalers, he says.
You may also be interested in...
McKesson In Final Phase Of Negotiating Fee-For-Service Contracts
The wholesaler anticipates 80% of compensation from manufacturers will be recorded under the new contract model by Oct. 1. Pfizer continues to be a significant holdout within the transition to fee-for-service, McKesson says.
McKesson In Final Phase Of Negotiating Fee-For-Service Contracts
The wholesaler anticipates 80% of compensation from manufacturers will be recorded under the new contract model by Oct. 1. Pfizer continues to be a significant holdout within the transition to fee-for-service, McKesson says.
ABC Still Optimistic On Fee-For-Service Despite Dropping Earnings Estimates
AmerisourceBergen still aims to have most manufacturers under fee-for-service agreements by the end of 2005. Although ABC has not set a March 31 deadline for fee-for-service contracts like Cardinal and McKesson, CEO Yost says "there is nothing in the market place that would imply that we are slower" at making the transition.